Chardan analyst initiates coverage of MNPR with "Buy" rating based on growth potential.

From Yahoo Finance: 2025-06-26 15:24:00

Monopar Therapeutics Inc. (NASDAQ: MNPR) was named one of the top 10 unstoppable stocks to buy by Hedge Funds. Chardan analyst Keay Nakae initiated coverage with a “Buy” rating and a price objective of $60, citing potential in its late-stage Wilson disease treatment and early-stage radiopharmaceutical pipeline.

Monopar Therapeutics Inc. (NASDAQ: MNPR) presented long-term efficacy and safety data for ALXN1840, supporting its potential as a treatment for Wilson disease. Results from 3 clinical trials showed sustained clinical benefits over a 2.63-year treatment period. The company also received authorization to proceed with a physician-sponsored Expanded Access Program for investigational imaging and therapeutic agents.

While MNPR shows growth potential, some AI stocks offer higher returns with limited risk. For those seeking promising AI stocks with significant upside potential, consider exploring alternative options. Check out reports on the cheapest AI stocks for potential investments.

Stay informed with more insights on cheap AI stocks and unstoppable growth stocks. Disclosure: None.



Read more at Yahoo Finance: Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy